206 related articles for article (PubMed ID: 23361589)
1. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.
Patel AR; Chougule MB; I T; Patlolla R; Wang G; Singh M
Pharm Res; 2013 May; 30(5):1435-46. PubMed ID: 23361589
[TBL] [Abstract][Full Text] [Related]
2. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Singh M
Pharm Res; 2006 Sep; 23(9):2094-106. PubMed ID: 16902813
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Fulzele SV; Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2006 Mar; 58(3):327-36. PubMed ID: 16536899
[TBL] [Abstract][Full Text] [Related]
4. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers.
Patlolla RR; Chougule M; Patel AR; Jackson T; Tata PN; Singh M
J Control Release; 2010 Jun; 144(2):233-41. PubMed ID: 20153385
[TBL] [Abstract][Full Text] [Related]
5. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.
Haynes A; Shaik MS; Chatterjee A; Singh M
Pharm Res; 2005 Mar; 22(3):427-39. PubMed ID: 15835749
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
Gadgeel SM; Wozniak A; Ruckdeschel JC; Heilbrun LK; Venkatramanamoorthy R; Chaplen RA; Kraut MJ; Kalemkerian GP
J Thorac Oncol; 2008 Nov; 3(11):1293-300. PubMed ID: 18978565
[TBL] [Abstract][Full Text] [Related]
7. Nanostructured lipid carrier (NLC) based gel of celecoxib.
Joshi M; Patravale V
Int J Pharm; 2008 Jan; 346(1-2):124-32. PubMed ID: 17651933
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Mu XY; Dong XL; Sun J; Ni YH; Dong Z; Li XL; Sun EL; Yi Z; Li G
Asian Pac J Cancer Prev; 2014; 15(1):69-73. PubMed ID: 24528083
[TBL] [Abstract][Full Text] [Related]
9. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
10. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Zhang H; Li Z; Wang K
Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
[TBL] [Abstract][Full Text] [Related]
11. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
[TBL] [Abstract][Full Text] [Related]
12. Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.
Park W; Oh YT; Han JH; Pyo H
J Exp Clin Cancer Res; 2008 Nov; 27(1):66. PubMed ID: 19000324
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Shaik MS; Chatterjee A; Jackson T; Singh M
Int J Cancer; 2006 Jan; 118(2):396-404. PubMed ID: 16052515
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Schneider BJ; Kalemkerian GP; Kraut MJ; Wozniak AJ; Worden FP; Smith DW; Chen W; Gadgeel SM
J Thorac Oncol; 2008 Dec; 3(12):1454-9. PubMed ID: 19057272
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non‑small cell lung cancer cells in vitro and in vivo.
Zhang H; Li Z; Wang K; Ren P
Oncol Rep; 2015 Mar; 33(3):1079-88. PubMed ID: 25524805
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Nugent FW; Mertens WC; Graziano S; Levitan N; Collea R; Gajra A; Marshall J; McCann J
Lung Cancer; 2005 May; 48(2):267-73. PubMed ID: 15829328
[TBL] [Abstract][Full Text] [Related]
17. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
18. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
[TBL] [Abstract][Full Text] [Related]
19. [Docetaxel and novel strategies in the treatment of NSCLC].
Longo F; Mansueto G
Tumori; 2005; 91(6):suppl 11-22. PubMed ID: 16457162
[No Abstract] [Full Text] [Related]
20. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Chen L; He Y; Huang H; Liao H; Wei W
Med Oncol; 2008; 25(2):161-71. PubMed ID: 18172786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
